Anticoagulants drugs direct trombin inhibitors

被引：1

作者：

Lecompte, T. ^{[1
,2
]}

Toussaint-Hacquard, M. ^{[1
]}

Devignes, J. ^{[1
]}

机构：

[1] CHU Nancy, Hemostase Serv Hematol Biol, Nancy, France

[2] Nancy Univ Henri Poincare, Fac Med, Nancy, France

来源：

ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION | 2009年 / 28卷

关键词：

Coagulation; Thrombin; Anticoagulants; DIRECT THROMBIN INHIBITOR; ORAL DIRECT THROMBIN; DABIGATRAN ETEXILATE; PHARMACODYNAMICS; PHARMACOKINETICS; HIRUDIN; THERAPY; HEPARIN; TIME;

D O I：

10.1016/S0750-7658(09)72458-X

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

The aim of this review is to explain the central role of thrombin in haemostasis and the main pharmacological features of the anticoagulants that are direct inhibitors of thrombin, with emphasis on orally active small molecules. Owing to the complexity of the clotting system only well designed and conducted studies can tell us which drug is the most useful, safe and convenient to limit each type of thrombosis and what are the appropriate dosage and management. Parenterally administered direct thrombin inhibitors require laboratory monitoring, whereas dabigatran, orally active, does not. (C) 2009. Elsevier Masson SAS. All rights reserved.

引用

页码：S3 / S7

页数：5

共 16 条

[1] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].

Blech, Stefan ;

Ebner, Thomas ;

Ludwig-Schwellinger, Eva ;

Stangier, Joachim ;

Roth, Willy .

DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399

[2] Structure and interaction modes of thrombin [J].

Bode, W .

BLOOD CELLS MOLECULES AND DISEASES, 2006, 36 (02) :122-130

[3] ACTIVATED CLOTTING TIME AS AN APPROPRIATE TEST TO COMPARE HEPARIN AND DIRECT THROMBIN INHIBITORS SUCH AS HIRUDIN OR RO-46-6240 IN EXPERIMENTAL ARTERIAL THROMBOSIS [J].

CARTEAUX, JP ;

GAST, A ;

TSCHOPP, TB ;

ROUX, S .

CIRCULATION, 1995, 91 (05) :1568-1574

[4] Patient-specific antiplatelet therapy [J].

Conde, ID ;

Kleiman, NS .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2004, 17 (01) :63-77

[5] Thrombin interactions [J].

Di Cera, E .

CHEST, 2003, 124 (03) :11S-17S

[6] Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development [J].

Eriksson, Bengt I. ;

Quinla, Datfiel J. ;

Weitz, Jeffrey I. .

CLINICAL PHARMACOKINETICS, 2009, 48 (01) :1-22

[7] A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial [J].

Eriksson, BI ;

Dahl, OE ;

Büller, HR ;

Hettiarachchi, R ;

Rosencher, N ;

Bravo, ML ;

Ahnfelt, L ;

Piovella, F ;

Stangier, J ;

Kälebo, P ;

Reilly, P .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :103-111

[8] Structure-based design of novel potent nonpeptide thrombin inhibitors [J].

Hauel, NH ;

Nar, H ;

Priepke, H ;

Ries, U ;

Stassen, JM ;

Wienen, W .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (09) :1757-1766

[9]

Laposata M, 1998, ARCH PATHOL LAB MED, V122, P799

[10] Thrombin formation [J].

Mann, KG .

CHEST, 2003, 124 (03) :4S-10S

← 1 2 →